Patents by Inventor Daniel Attilio Vallera

Daniel Attilio Vallera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Deimmunized therapeutic compositions and methods
    Patent number: 11208634
    Abstract: This disclosure provides a bispecific ligand directed toxin (BLT) that includes a diphtheria toxin (DT) molecule that has been mutated to create a DT molecule that induces less of an immune response than native diphtheria toxin. The deimmunized DT molecule is fused with targeting ligands to create a fusion protein that can selectively deliver the deimmunized DT to target cells to kill the target cells.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 28, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Daniel Attilio Vallera
  • THERAPEUTIC COMPOUNDS AND METHODS
    Publication number: 20210395326
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Application
    Filed: August 6, 2021
    Publication date: December 23, 2021
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • Therapeutic compounds and methods
    Patent number: 11098100
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • Therapeutic compounds and methods
    Patent number: 11098101
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • THERAPEUTIC COMPOUNDS AND METHODS
    Publication number: 20200148737
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Application
    Filed: November 15, 2019
    Publication date: May 14, 2020
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • THERAPEUTIC COMPOUNDS AND METHODS
    Publication number: 20200087369
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Application
    Filed: September 5, 2019
    Publication date: March 19, 2020
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • THERAPEUTIC COMPOUNDS AND METHODS
    Publication number: 20180282386
    Abstract: This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
    Type: Application
    Filed: October 6, 2016
    Publication date: October 4, 2018
    Inventors: Daniel Attilio Vallera, Jeffrey S. Miller
  • DEIMMUNIZED THERAPEUTIC COMPOSITIONS AND METHODS
    Publication number: 20180273920
    Abstract: This disclosure provides a bispecific ligand directed toxin (BLT) that includes a diphtheria toxin (DT) molecule that has been mutated to create a DT molecule that induces less of an immune response than native diphtheria toxin. The deimmunized DT molecule is fused with targeting ligands to create a fusion protein that can selectively deliver the deimmunized DT to target cells to kill the target cells.
    Type: Application
    Filed: September 30, 2016
    Publication date: September 27, 2018
    Inventor: Daniel Attilio Vallera